Gene Therapy to Cure Blindness Gets Approval from FDA Advisers
On Thursday, a review panel from the U.S. Food and Drug Administration (FDA) gave their stamp approval for an experimental gene therapy to cure blindness. The treatment is for a genetically inherited blindness known as Leber Congenital Aumaurosis. Leber Congenital Aumaurosis (LCA) is a rare inherited eye disease that appears at childbirth or during the first few months of a person’s life. This eye disease was said to affect one in every 40 thousand newborns.